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ABSTRACT 
Statins are widely prescribed and used chronically, but we know little about the effects 
on long-term protein homeostasis during stress and aging. Our aim was to quantify the effect of 
statins on stress-induced protein damage. We administered atorvastatin in a dose-response 
curve in Caenorhabditis elegans under naïve control conditions and in conditions of hypertonic 
and heat stress known to induce muscle damage measurable as countable puncta in a 
polyglutamine aggregation model of damage. We observed that there is significant 
polyglutamine aggregation variability among worms at baseline and thus further study requires 
within experiment baseline controls, per worm. Our results are that statins exacerbate (p<0.05) 
the amount of protein damage induced by hypertonic and heat stress in a muscle protein 
reporter of polyglutamine aggregation. Many patients taking statins long-term report adverse 
muscular side effects may be experiencing some tissue-level pathophysiology associated with 
statins; our results support an effect of statins on muscular protein damage during stress. 
Further study is required to understand the effects of statins on age-induced protein 
homeostasis, long-term effects of augmented statin-induced damage, and translation to human 
studies.  
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CHAPTER 1 – REVIEW OF LITERATURE 
 
HISTORICAL INFORMATION ABOUT STATINS 
Statins were discovered ~4 decades ago and are now the largest class of drugs 
prescribed, globally (1, Figure 1). Much remains unknown, however, about the side effects of 
chronic use. While the average person takes statins ~40 years to protect against cardiovascular 
diseases, 30% of patients discontinue statin use following an adverse side effect (2). Due to 
adverse effects of statins, the American Heart Association (AHA) recommends dynamic patient 
and physician relationships to find a statin that is tolerated and fits the patient’s profile (Table 
1, Table 2). With one in four adults over 40 using statins, ideal statin therapy should promise 
increase in quality of life, with minimal discomfort, muscle weakness, and pain (3). 
 
 
 
Figure 1: The Development of Statins (4) 
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Patient Condition Treatment 
20-75 and LDL-C ≥ 190 mg/dl               High-intensity statin without risk assessment 
40-75 and LDL-C ≥ 70 mg/ dl               Moderate-intensity statin with risk 
assessment to consider high-intensity statin 
 
Table 1: American Heart Association’s Statin Guidelines (5) 
 
Statin Type Solubility, 
Half Life (hrs), 
Bioavailability (%) 
Intensity 
(Low Intensity – Lowers LDL-C by <30%) 
(Moderate Intensity – lowers LDL-C by 30%-49%) 
(High Intensity – lowers LDL-C by ≥ 50%) 
   
(Lovastatin) Lipophilic, 
13.37 hrs, 
5% 
20 mg = (Low Intensity) 
40 mg = (Moderate Intensity) 
 
Zocor 
(Simvastatin) 
Lipophilic, 
4.85, 
5% 
10 mg = (Low Intensity) 
20-40 mg = (Moderate Intensity) 
Pravachol 
(Pravastatin) 
Hydrophilic, 
1.8, 
17% 
10-20 mg = (Low Intensity) 
 40 mg = (Moderate Intensity) 
Lescol 
(Fluvastatin) 
Lipophilic, 
3, 
24% 
20-40 mg = (Low Intensity) 
 
Lipitor 
(Atorvastatin)  
Lipophilic, 
14, 
14% 
10 mg = (Moderate Intensity) 
40 mg = (High Intensity) 
*Today’s most popular statin. 
Crestor 
(Rosuvastatin) 
Lipophilic, 
19, 
20% 
5 mg = (Moderate intensity) 
20 mg = (High intensity) 
*Today’s strongest statin. 
Baycol 
(Cerivastatin) 
Lipophilic, 
2-3, 
60% 
(High Intensity) 
*Removed from the market following 50 deaths 
attributed to statin induced rhabdomyolysis. 
 
Table 2: Statin Profile/Types (6, 27, 28) 
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Cardiovascular diseases result in one out of every three deaths globally and are the 
leading cause of death in both men and women in the United States (7, 8). Statins are among 
the most commonly prescribed drugs for reducing cholesterol levels and work mechanistically 
by HMG-CoA reductase inhibition in the mevalonate pathway (Figure 2). Through the 
mevalonate pathway, mevalonate, a precursor of cholesterol, is synthesized from HMG-CoA (9). 
Statins target the mevalonate pathway to regulate the production of cholesterol, but indirectly 
also regulate lipoprotein signaling (10). Data suggests that the indirect effects on lipoproteins 
may increase susceptibility to protein tissue and muscle damage with stress (e.g., exertional 
rhabdomyolysis) including exercise-induced stress (11, 12). Myopathy (muscle weakness) and 
myalgia (muscle pain) affect ~10% of the 35 million Americans taking statins (6). This pain-
related side-effect contributes to some of the decisions of ~25-60% of patients to stop statin 
use (13). 
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Figure 2: Statins Pathway (14) 
 
STATIN SIDE EFFECTS 
The most common adverse effect of statin use, is myopathy and myalgia (6). The 
mechanism may be related to how statin signaling pathways are related to protein homeostasis 
or proteostasis, the collection of processes that support protein synthesis and function. The 
mevalonate pathway produces ubiquinone (coenzyme Q), cholesterol, dolichol, and prenylated 
proteins. While statins limit LDL-cholesterol, they also affect the production of compounds 
crucial to the maintenance and structural integrity of proteins (15). In addition, CoQ10 is mainly 
carried by LDL cholesterol, thus the lowering of LDL cholesterols lowers CoQ10. Coenzyme Q is 
responsible for remodeling skeletal muscle and functions in electron transport chain of the 
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mitochondria in producing ATP, decreases under statin therapy (16). However, studies that 
supplement Coenzyme Q for patients with myalgia show little to no effects on pain 
management (17).  
In some patients, statins reportedly cause myopathy and muscle damage, ranging from 
muscle weakness to rhabdomyolysis, a life-threatening syndrome caused by muscle breakdown 
(12). In the PRIMO Observational study, 832 out of 7924 patients reported pain with 315 
patients reporting pain when using muscles and 31 patients being confined to bed from pain 
(18). While actual muscle ruptures are rare and often confused with tendon ruptures, a 
Netherlands pharmaceutical database has logged >165 cases of muscle rupture linked to statin 
use (19). The mechanisms by which statins increase muscle damage remains unknown. In a 
survey that reported 1,074 French statin users, 38% reported muscular symptoms that 
prevented everyday activities and a decrease in quality of life (13).  
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Statin induced muscle 
effects  
Statin induced neurological 
effects  
Additional general statin 
induced effects  
-Difficultly walking, overall 
weakness, did not improve 
following resistance exercise, 
that dissipated following the 
stopped usage of statin.  
 
-Rhabdomyolysis leading to 
multiple organ failure and 
death is the most affects less 
than 0.1% of statin users. 
 
-Creatine Kinase levels, 
biomarkers of muscle 
damage, can rise up to 10 
times the normal limit under 
statin therapy in around 7-
29% of users. 
-Mixed reports and studies 
on statins causing psychiatric 
disorders, memory loss, or 
slowing dementia 
progression. Regardless of 
positive or negative effects, 
there is a lack of causality 
and prevalence is rare.  
 
- A meta-analysis of 25 
randomized controlled trials 
conclude that that statins 
have no effect on cognition. 
They neither decrease or 
increase cognitive 
performance 
-Statin induced liver injury 
affects ~3% of statin users. 
 
-Statins can increase risk of 
diabetes by 9% following 4 
years of statin adherence. 
 
-Statins can increase risk of 
acute kidney injury in the 
first 4 months of statin 
adherence 
 
-Sleep quality may be 
disrupted under certain 
stains but dissipate following 
a change in statins. 
Table 3: Reported Side Effects when taking Statins (20-25) 
 
CAENORHABDITIS ELEGANS ANIMAL MODEL 
Caenorhabditis elegans have a conserved mevalonate pathway with cholesterol-
independent, proteostatic branches of the statin signaling pathways. Less than half a dozen 
studies have studied statin effects in C. elegans, but it is known that worms lacking HMG-CoA 
lack protein prenylation and have an increased unfolded protein response (UPR) (15). C. 
elegans allows rapid alteration of gene expression through RNAi gene knockdown. In ongoing 
studies, genetic knockout of key components of statin signaling along the mevalonate pathway 
will allow determination of specific molecular regulators of statin effects on protein structure 
and function. C. elegans’ ~40% genetic homology to humans (26), availability of reporter strains 
that allow easy visual assay of muscle and neuronal damage, genetic tractability, and short 
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lifespan make it a powerful comparative animal model for studying the effects of statins on 
muscle and neuronal proteostasis. 
 
STATEMENT OF THE PROBLEM AND RESEARCH HYPOTHESIS 
Despite the prevalence of statin use, little is known about the mechanisms and long-
term impacts of statins on human aging, protein function, and muscular injury. Understanding 
the chronic implications of statin use and mechanisms by which statins may affect aging tissues 
is critical given the widespread use and potential impacts on individuals participating in physical 
activity, perhaps in stressful (hot, humid, with dehydration) environments. The aim of the study 
was to use the tractable Caenorhabditis elegans animal model to 1) test the hypothesis that 
statin treatment will cause increased muscle damage during stress.  
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CHAPTER 2 – METHODS 
 
Materials and Methods 
C. elegans strain and maintenance 
AM140 rmIs132[Punc-54::Q35::YFP] worm strain was cultured in 20° C on 100mm petri 
dishes filled with 51mM NaCl NGM and coated with 350µL OP50 E. coli. Worms were 
maintained to avoid starvation by regular transfer to new food. The AM140 worm strain 
contains a fluorescent reporter of muscle damage that expresses a yellow-fluorescent-protein 
(YFP) in the promoter of a muscle-specific protein (unc-54). 
NGM was made following a specific recipe of 1.49g NaCl, 1.25g bacto-peptone, and 8.5g 
bacto-agar and 500µL deionized water. These ingredients were combined in a 1000mL media 
bottle and after autoclaving on a 30-minute liquid cycle, the media was cooled at room 
temperature. After cooling, 500µL of cholesterol (to support reproduction), 500µL magnesium 
sulfate, 500µL calcium chloride, and 12.5mL of potassium phosphate were added to the media. 
Following the addition of these salts, the liquid media was poured into 100mm and 60mm petri 
dishes and allowed to solidify at room temperature.  
OP50 E. coli for bacterial lawns were cultured in LB broth through the placement of a 
single colony of bacteria in 10mL of LB broth and incubated at 37° C for 12-18 hours in a shaking 
incubator (225rpm). Following incubation, 350µL of the overnight OP50 E. coli culture was 
pipetted onto the solidified media plate, spread using a sterile spreader, and allowed to grow 
into a bacterial lawn at 37° C. 
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To synchronize (to same developmental larval stage) and decontaminate worms for 
experiments, a bleach technique was used. A bleach solution kills all but C. elegans eggs which 
are transferred to new plates. The bleach technique includes washing the worms off of an NGM 
plate using 51mM NaCl buffer and pipetting the worms and buffer solution into a sterile 15mL 
conical tube. After spinning the worms down in a centrifuge at 2,000 rotations per minute 
(rpm) for one minute, the supernatant of buffer was removed and the conical tube was filled 
with additional buffer. This technique was repeated four times. After washing, a bleach solution 
of 1mL bleach, 250µL NaOH, and 3.75mL of autoclaved water was added to the conical tube 
containing the worms. The conical tube was shaken vigorously by hand for five minutes and the 
reaction was stopped with the addition of autoclaved water. After the addition of the 
autoclaved water, the conical tube was spun in the centrifuge for three minutes at 1,200 rpm. 
Following the centrifugation, the supernatant was removed and the conical tube was filled with 
NGM buffer and spun at 1,200rpm for 3 minutes. This wash was repeated two additional times.  
After the final centrifugation, the remaining bleached eggs were pipetted to clean (no 
OP50 E. coli) 51mM NaCl NGM plates. These clean plates were left to incubate at 20 degrees 
Celsius overnight, allowing all eggs to hatch. The following day, the starved L1 worms are all 
synchronized because during starvation, all mixed populations of L1s will enter a dauer phase. 
They are fed by transferring them to NGM plates containing OP50 E. coli. After being fed, 
worms will grow together and reach the L4 stage, where they can be used for experiments.  
 
Statin Administration 
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Lipitor (Atorvastatin), created by Pfizer, is the best-selling statin in the United States (1). 
In an efficacy study and economic analysis of statins, atorvastatin has significantly less mean 
total treatment costs, the highest success rate for patient outcomes, and significantly reduces 
triglycerides and LDL by at least 10% more than simvastatin, pravastatin, lovastatin, and 
fluvastatin (29, 30). We chose to use atorvastatin calcium for statin administration because it is 
widely used and well-tolerated, thus making it the most applicable to eventual translation in 
the human model. Atorvastatin pill drugs were provided by Dr. Beth Taylor’s laboratory. The 
pure chemical form was purchased from Fisher Scientific (CATALOG INFO) and stored at room 
temperature 20° C. 80mg atorvastatin pills were pulverized using a mortar and pestle and 
dissolved in methanol (MeOH) to create weight by volume solutions of varying concentrations. 
For solutions made from pure atorvastatin powder, powder was directly added to MeOH. 
Atorvastatin liquid solution was added directly to the in 3mL solid media agar (NGM) to final 
mM concentrations 0.1, 0.125, 0.25, 0.375, 0.5, 0.75, and 1.0mM. Synchronized worms, grown 
on control, isotonic media (51mM NaCl NGM) are placed on 12-well plates for growth and drug 
control. Columns treated with solvent only (methanol or water) served as no-drug and vehicle 
only controls. 
 
Quantification of Q35::YFP aggregates for Atorvastatin, Hyperosmotic, and Heat Stress 
 Q35::YFP aggregates were counted manually. During imaging, worms were live and 
moving. 8-hour statin survival assays of C. elegans were completed using 12 well petri plates. 
3mL of media in 51mM and 200mM concentrations of NaCl were pipetted into the wells and 
allowed to solidify (one column in each well plate used per stress condition). After adding 20µL 
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of OP50 E. coli, 3 x AM140 L4 staged worms were staged with a worm picker to each well. For 
Atorvastatin stress assays, worm was screened at baseline, 0h (hour), and at every 2-hour 
interval for 8 total hours. This procedure was completed with 0mM (no additive), 0mM 
(MeOH), 0mM (H2O), 0.1, 0.125, 0.25, 0.375, 0.5, 0.75, and 1.0mM. Atorvastatin-supplemented 
media and control media for 51mM and 200mM NaCl media concentrations. The worms were 
screened under a fluorescent microscope to count the number of polyglutamine (polyQ) 
aggregates in each stress condition.  
For the heat stress assays, 3 x AM150 L4 worms were screened at baseline, 0h (hour), 
and for 5 hours on 51mM NaCl NGM plates at 35° C, 37° C, and 40° C for without heat recovery. 
This procedure was further carried on 51mM NaCl NGM plates at 35° C with 5 hours recovery. 
1-hour heat stress at 40° C with 4 hours recovery was ran in conjunction with 0mM (MeOH), 
0.25mM, 0.375mM, 0.5mM, 0.75mM, 1mM atorvastatin supplemented media and control 
media. After heat and statin stress, worms were taken out of incubator and placed in 20 °C 
incubator to allow for worm heat recovery and prevent worm death. Following recovery, 
worms were placed under the microscope for imaging. A fluorescent filter was used to allow for 
the visualization of Q35 fluorescent aggregates (puncta). These puncta were either counted 
manually live.  
 
Statistical analysis 
All data is presented as means ± SD. Pairwise comparisons were assessed for statistical 
significance (p<0.05) using paired t tests.  
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CHAPTER 3 – STATIN (PILL) EFFECTS ON HYPERTONIC STRESS-INDUCED PROTEIN DAMAGE  
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Figure 3. Effect of pulverized atorvastatin pill and hypertonic stress on glutamine aggregate 
formation. A. 0h, baseline, aggregate count. B. 2h, aggregate count. C. 4h, aggregate count. D. 
6h, aggregate count. E. 8h, aggregate count. * represents statistically significant (p<0.05) 
differences between pulverized atorvastatin pill dose and respective 0 dose control to vehicle. ‡ 
represents statistically significant (p<0.05) differences between 0 MeOH and 0 no additive. a 
represents statistically significant (p<0.05) differences between experimental conditions and 
respective baseline (0h). b represents statistically significant (p<0.05) differences between 
isotonic/dehydrated (51mM) vs. hypertonic/dehydrated (200mM) conditions. Navy bars 
represent worms cultured and maintained on 51mM NaCl isotonic NGM plates and salmon bars 
represents worms cultured on 51mM NaCl NGM and exposed to 200mM NaCl NGM at the start 
of the experiment. Number of worms screened at baseline, start of experiment (n=432 total): 
n=36 (0 no additive), n=108 (0 MeOH), n=36 (0.1mM), n=36 (0.125mM), n=36 (0.25mM), n=36 
(0.375mM), n=36 (0.5mM), n=36 (0.75mM), n=72 (1mM) (Table 4,5) 
 
Results 
Figure 3A. Glutamine aggregation varies at baseline, requiring 0 time point controls within 
experiments, per worm.  
With first exposure (<5 min) of drug and concomitant environmental stress (i.e., 
hypertonic stress), worms exhibit varying numbers of puncta. Statistically significant (p<0.05) 
differences between 0.5mM and 1mM atorvastatin treated worms were observed at time 0. It 
is unlikely that <5 min induced 2-fold increase in aggregates, and thus important that 0 time 
point controls be included for all worms in experiments testing drug and/or stress exposure. 
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There were no significant differences between worms placed on 51mM NaCl NGM vs. 200mM 
NaCl NGM (p>0.11) at baseline. In addition, there were no significant differences between no 
additive and vehicle (MeOH: methanol) for 51mM NaCl NGM (p>0.14) and for 200mM NaCl 
NGM (p>0.95).  
 
Figure 3B. Glutamine aggregation and worm deaths occurs within 2 hours of exposure. Within 2 
hours of drug and concomitant environmental stress (e.g., hypertonic stress, atorvastatin 
stress), worms exhibit an increase in glutamine aggregation from protein damage and a 
decrease in lifespan survival. Some worms at higher atorvastatin and hypertonic stresses, are 
scored as dead within 2 hours. There are 21 worm deaths in the 51mM group and 38 worm 
deaths in the 200mM group, at high stress 0.5mM, 0.75mM, and 1mM atorvastatin groups. 
While there were not a significant number of puncta accumulated between the 51mM NaCl 
NGM vs 200mM NaCl NGM hyperosmotic group (p>.06), we do see more deaths accumulated 
in the hyperosmotic group within 2 hours of exposure to the stresses.  
In addition, there are significantly less puncta (p<0.01) between the 0 No additive 51mM 
group at 2h than at 0h. This is highly unlikely and was so because (n=9) less worms with a 
higher aggregate count were not counted due to time constraints; the remaining (n=9) worms 
there were counted had a significantly smaller aggregate average leading to an ostensibly 
smaller amount of aggregates. Excluding the 0 No Additive group, due to missed worms for the 
count, there were no significant (p>.06) differences in aggregate counts between 51mM NaCl 
NGM and 200mM NaCl exposure 2 hour at every time point with the same atorvastatin 
treatment.  
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Figure 3C. Glutamine aggregation and worm deaths skew the dose response curve within 4 
hours of exposure. High counts of worm deaths at high atorvastatin and osmotic stress, shifts 
the aggregate count. Anything beyond 0.375mM pulverized atorvastatin pill is too toxic of a 
dose as it leads to worm deaths. There are 5 deaths in the 0.25mM concentration and then 16 
deaths in the 0.5mM concentration. Due to time constraints, experiment 2 did not screen at 4h 
for both the 51mM and 200mM for the no additive, MeOH vehicle, 0.125mM, and 1mM groups. 
The worms in 1mM atorvastatin and 200mM NaCl all died from every experiment except for the 
ones in experiment 2 that were not screened. Within 4 hours of worm exposure there are 60 
worm deaths in the 200mM group and 28 worm deaths in the 51mM group, at high stress 
0.25mM, 0.5mM, 0.75mM, and 1mM atorvastatin groups.  
 
Figure 3D. Higher osmotic stress in the same drug concentration does not significantly increase 
glutamine counts within 6 hours of exposure. 200mM NaCl causes double the amount of deaths 
than 50mM NaCl conditions at time point 6. Within 6 hours of worm exposure there is double 
the amount of worm deaths in the 200mM compared to the 51mM NaCl NGM group without 
significant (p>0.08) differences in glutamine aggregates, at high stress 0.125mM, 0.25mM, 
0.375mM, 0.5mM, 0.75mM, and 1mM atorvastatin groups. Even with the deaths, there are 
more total alive worms at 6h than 4h because experiment 2 was not screened at hour 4. While 
the data suggests that “0 MeOH” leads to significantly more puncta aggregates than “0 no 
additive,” the sample (n=43) size for 0 MeOH is quadruple that of the sample (n=9) size of no 
additive for no additive in the 51mM NaCl treatment. The larger sample size in MeOH 
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ostensibly has higher glutamine aggregates but this is so because of the sample size. Similarly, it 
appears as if 0.25mM has similar counts of puncta to 0.5mM, 0.75mM, and 1mM, but it is 
important to note that doses higher than 0.375mM pulverized pill cause more > 50% worms 
deaths. A consistent sample size is needed to truly determine the dose-response curve.  
 
Figure 3E. 0.25 and 0.375mM atorvastatin doses at 8 hours of exposure contribute to the most 
aggregates and least deaths. 0.5mM, 0.75mM, and 1mM Atorvastatin concentration have a 70-
90% death rate by hour 8 of hypertonic and atorvastatin stress. While there was a total of 32 
worms for each of the 0.25mM, 0.375mM, 0.5mM, 0.75mM, and 1mM conditions, there were 
only 10, 9, and 3 worms alive for the 0.5mM, 0.75mM, and 1mM conditions. With a 70 – 90% 
death rate, any atorvastatin from pill concentration above 0.5mM is much for the survival of 
AM140 worms. Glutamine aggregation occurs within 8 hours of exposure at a significant 
difference specific to the 0 MeOH condition for the 51mM NaCl NGM in the 0.25mM, 0.5mM, 
and 1mM NaCl group. With experiments from 5 different pooled experiments in the previous 
time marks, the 8 hours of worm exposure only holds data from experiments 3, 4, 5 and not 
from 1 and 2, as experiments 1 and 2, stopped screening at 6h. The lack of data from 
experiments 1 and 2 decrease the total worm count conditions for 0 No additive, 0 MeOH, 
0.125, and 1mM.  
 
Discussion 
 8-hour pulverized atorvastatin pill and hyperosmotic stress experiments were 
accumulated from 5 experiments. With atorvastatin stress and concomitant hypertonic stress, 
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worms exhibit an increase in protein damage and a decrease in lifespan survival. Experiments 
indicate a decrease in survival of worms at the hypertonic dose (200mM) compared to the 
isotonic dose (51mM), but no significant increase in puncta.  
 While glutamine aggregation varies at baseline, the protein aggregation forms are rates 
specified to their experimental condition. Within 2 hours, we noted that many worms are dying 
before they develop puncta. At high statin concentrations, (0.5mM, 0.75mM, and 1mM), the 
dehydrated (200mM NaCl NGM) group had significantly more deaths than the hydrated (51mM 
NaCl NGM) group, at all drug conditions without a significant increase in puncta. It is possible 
that the atorvastatin pill is too toxic at higher doses, leading to death unassociated or before 
protein damage occurs. Within 4 hours of exposure, doubling the statin dose from 0.25mM to 
0.5mM triples the amount of deaths. At 6h, we note that moving from 50mM to 200mM causes 
double the amount of deaths at high statin concentrations. Thus, we conclude, that when 
administering drug stress with pulverized statin pills, the doses should not exceed 0.5mM as it 
leads to deaths before an adequate development of puncta over time. While the worms that do 
survive in those conditions do develop a significant number of puncta in compared to their 
baseline, the sample size dramatically decreases. 0.25 and 0.375mM atorvastatin doses appear 
to cause to the most aggregates and least deaths. 0.5mM, 0.75mM, and 1mM Atorvastatin 
concentration have a 70-90% death rate by hour 8 of hypertonic and atorvastatin stress. 
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CHAPTER 4 – PURE STATIN EFFECTS ON HYPERTONIC STRESS-INDUCED PROTEIN DAMAGE 
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Figure 4. Effect of pure atorvastatin salt and hypertonic stress on glutamine aggregate 
formation. A. 0h, baseline, aggregate count. B. 2h, aggregate count. C. 4h, aggregate count. D. 
6h, aggregate count. E. 8h, aggregate count. * represents statistically significant (p<0.05) 
differences between pulverized atorvastatin pill dose and respective 0 dose control to vehicle. ‡ 
represents statistically significant (p<0.05) differences between 0 MeOH and 0 no additive. a 
represents statistically significant (p<0.05) differences between experimental conditions and 
respective baseline (0h). b represents statistically significant (p<0.05) differences between 
isotonic/dehydrated (51mM) vs. hypertonic/dehydrated (200mM) conditions. Navy bars 
represent worms cultured and maintained on 51mM NaCl isotonic NGM plates and salmon bars 
represent worms cultured on 51mM NaCl NGM and exposed to 200mM NaCl NGM at the start 
of the experiment. Number of worms screened at baseline, start of experiment (n=180 total): 
n=9 (0 H2O), n=54 (0 MeOH), n=27 (0.1mM), n=27 (0.25mM), n=27 (0.375mM), n=27 (0.5mM), 
n=27 (1mM MeOH), n = 9 (1mM H2O) (Table 6,7). 
 
Results 
Figure 4A: Glutamine aggregation varies at baseline, requiring 0 time point controls within 
experiments, per worm. There is little to no variability at baseline, puncta differences were less 
than one. Regardless, baseline variability was determined to interpret any effects observed 
with drug and/or stress treatments on glutamine aggregation. The significant (p<0.02) 
differences between worms placed on 51mM NaCl NGM vs. 200mM NaCl NGM at 1 MeOH is 
0.6 of a difference, which is not even countable as a single puncta. There is a difference in 
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decimal figures because averages were taken for the worms. There are no significant (p>.6) 
difference between the methanol or water vehicle at baseline.  
 
Figure 4B. Glutamine aggregation without worm deaths occurs within 2 hours of exposure to 
Atorvastatin salt. At hour 2, there are no deaths at hour 2 even at high concentrations of 1mM 
atorvastatin for both 51mM and 200mM NaCl. In addition, the 1mM H2O vehicle did not have a 
significant (p>0.77) number of puncta compared to the 0 H2O concentration while the 1mM 
MeOH did have a significant (p<0.37) number of puncta compared to its 0 MeOH concentration. 
This may be so because atorvastatin is not soluble in water. The H2O vehicle wells are also very 
cloudy and thus more difficult to see the worms. Future research should use methanol.  
 
Figure 4C. Glutamine aggregate increases accordingly with increased dose at 4 hours of stress 
exposure. Glutamine aggregation occurs within 4 hours of exposure at a significant (p<1.7x10 -5) 
difference specific to time point 0 and the 51mM 0 MeOH group for the 0.375mM, 0.5mM, and 
1mM MeOH groups. The 1mM MeOH has the highest aggregate count and the 0.25mM has the 
lowest aggregate count. At hour 4, there are still no noted deaths but 4 of the worms in the 
0.5mM group may have climbed out of wells due to the atorvastatin stress. The 200mM group 
has significantly more puncta than both the 51mM NaCl 0 MeOH and 1 MeOH group (p<8.5x10-
20) and (p<2.3x10-5).  
 
Figure 4D: 200mM hyperosmotic stress increases the amount of aggregates compared to 50mM 
of the same dose. The data suggests that 1mM atorvastatin salt administered in MeOH for 
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51mM may be the optimal dose to yield the most glutamine aggregates without worm deaths. 
The 200mM 1 MeOH, while it does yield much aggregates, it is unclear whether the aggregates 
form due to hypertonic stress or the atorvastatin dose. This is so because there is no significant 
difference between the 1MeOH and 0MeOH concentration for 200mM at time point 6 (p>0.81).  
 
Figure 4E: Glutamine aggregates are greater in 1 MeOH than 1 H2O.  
Glutamine aggregation occurs within 8 hours of exposure at a significant difference specific to 
hour 0 in all groups tested (p<1.4x10-6). The 1 MeOH and 1 H2O have a significant difference to 
their specific controls at hour 8 (p<0.0002) and (p<0.006) respectively. The 1 MeOH has greater 
significant difference from its control possible because atorvastatin is more soluble in methanol 
than water. The significant difference between the 51 and 200mM group for both 0 MeOH and 
1 MeOH (p<1.06x10-13) and (p<3.86x10-7) demonstrates that 200mM does increase the 
aggregate counts.  
 
Discussion 
8-hour pure atorvastatin salt and hyperosmotic stress experiments were accumulated 
from 4 experiments. The pure atorvastatin salt was administered to rule out any factors the 
other compounds in the pill may have caused. With atorvastatin salt stress and concomitant 
hypertonic stress, worms exhibit increases in protein damage and without killing as many 
deaths. There may be a compound in the pulverized pill that leads to more worm deaths. 
Identical pure atorvastatin salt doses do not cause deaths as seen when using pulverized 
atorvastatin pill. With atorvastatin pill the 200mM group increases the risk of worm death 
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without an increase in glutamate aggregates; however, with atorvastatin salt, the 200mM 
group, increases the aggregate count without an increase in worm death. Thus, we conclude 
that atorvastatin salt is better than pulverized atorvastatin pills at creating a dose-response 
curve that increases glutamine aggregates without decreasing the sample size. There is a 
significant increase in puncta with the increase in statin dose, seen in all time points except for 
the baseline. 
The 1mM H2O group has more puncta compared to the 0 H2O group at all time points, 
excluding the baseline. This may be so because the atorvastatin was not soluble in the water. If 
it was not soluble in the water, it is not evenly dissolved in the agar and accessible by the 
AM140 worms. The 1 MeOH and 1 H2O have a significant difference to their specific controls at 
hour 8 of (p<0.0002) and (p<0.006) respectively. However, the 1 MeOH causes a greater 
significant difference from its control than the 1 H2O because atorvastatin is more soluble in 
methanol than water. 
 Hypertonic stress alone and paired with statins cause a higher count of glutamine 
aggregates than isotonic conditions or isotonic statin conditions. With the pure atorvastatin 
salt, the 200mM group doubles the number of puncta in the 1MeOH 51mM vs 1 MeOH 200mM 
group. The osmotic stress causes more protein aggregation than the statin does, this is evident 
as the 0mM statin + 200mM NaCl group has a similar number of puncta as the 1mM + 200mM 
NaCl group. Introducing hyperosmotic stress to a statin group significantly (p<3.8x10-7) 
increases the amount of protein aggregates. Thus, dehydration significantly increases protein 
damage in statin users.  
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CHAPTER 5 – COMBINED HEAT AND HYPERTONIC STRESS-INDUCED PROTEIN DAMAGE 
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Figure 5. Effect of varying heat stress on glutamine aggregate formation in isotonic and 
hypertonic conditions. A. 0h, baseline, aggregate count. B. 1h, aggregate count. C. 2h, aggregate 
count. D. 3h, aggregate count. E. 4h, aggregate count. F. 5h, aggregate count. G. 6h, aggregate 
count. H. 7h, aggregate count. * represents statistically significant (p<0.05) differences between 
varying heat stress conditions and the respective room temperature (20  oC) control. a 
represents statistically significant (p<0.05) differences between experimental conditions and 
respective baseline (0h). Navy bars represent worms cultured and maintained on 51mM NaCl 
isotonic NGM plates and salmon bars represents worms cultured on 51mM NaCl NGM and 
exposed to 200mM NaCl NGM at the start of the experiment. Number of worms screened at 
baseline, start of experiment (n=105 total): n=35 of (20oC), n=25 of (35oC), n=35 of (37 oC), and 
n=10 of (40 oC) (Table 8,9). 
 
RESULTS 
Figure 5A. Glutamine aggregation varies at baseline, requiring 0 time point controls within 
experiments, per worm. Glutamine aggregates were counted to determine whether there was 
significant variability per worm in different experimental conditions at the start of the 
experiment (within 5 minutes of treatment). This is critical to determine the baseline variability 
in interpreting any effects observed with drug and/or stress treatments on glutamine 
aggregation and the greater concept of body muscle damage acutely, and chronically. Worms 
were grown on control, isotonic media (51mM NaCl NGM) and placed onto either 51mM NaCl 
control wells or 200mM NaCl and then administered heat stress. Within 5 minutes, baseline 
numbers of puncta were counted. There is minor variability, all within 1 puncta of each other, 
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in number of puncta among healthy worms placed onto experimental conditions and thus we 
conclude that this data should serve as baseline for each respective experiment. There were no 
significant differences between worms placed on 51mM NaCl NGM vs. 200mM NaCl NGM 
(p>0.07). The data for heat and osmotic stress are pooled from multiple experiments that 
administer heat at different lengths and with different recovery times, hence why there may 
not be data points for each condition at each 1 hour mark.  
 
Figure 5B. 1 hour of heat stress is not enough time for glutamine aggregation. No worms die 
within 1 hour of heat administration, there is a decreased number of total worms, because not 
every experiment screened at 1 hour after we noted that there is no observable difference 
(p>0.2) within 1 hour of heat stress. 
 
Figure 5C. Significant increase in puncta, within 2 hours, is still less than an overall increase of 1 
puncta. 2 hour of heat stress without recovery, is not adequate time to observe a true 
development of puncta. Within 2 hours of exposure to heat conditions, the 51mM worms in the 
35 oC have an increase in number of puncta (p<0.001) to their baseline by 0; however, their 
overall puncta count is still less than 1. No worms die within 2 hours of heat administration, 
there is a decreased number of total worms, because not every experiment screened at hour 2, 
after we noted that there is no observable differences between the temperature conditions 
(p>0.16) within 2 hours of heat stress. 
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Figure 5D. Glutamine aggregation occurs within 3 hours of 35 oC and 37 oC heat stress. 3 hours 
of environmental stress (i.e., heat stress), worms exhibit varying numbers of puncta. Within 3 
hours of exposure to heat stress without recovery is an adequate time to observe significant 
(p<0.004) development of puncta in 35 oC, and 37 oC baseline, 0h. Additionally, they are also 
significantly (p<.01) different compared to the control of 20 oC at the same time point. No 
worms die within 3 hours of heat administration, there is a decreased number of total worms, 
because not every experiment screened at hour 3. 
 
Figure 5E. Glutamine aggregation and worm deaths occur at 4 hours of heat exposure. Within 4 
hours of exposure to heat conditions, the 51mM worms in the 35 oC and 37 oC have a significant 
difference (p<0.01) to their baseline. There are initially 15 worms screened at 37 oC but 10 of 
the worms died from the heat stress. The surviving 5 in the 37 oC have a significantly 
(p<5.92x10-8) higher aggregate number than the control 20 oC at the same time point. The 
worms in the 35 oC are also significantly (p<0.001) greater than the control 20 oC at the same 
time point. 
 
Figure 5F. Glutamine aggregation increases in relation to heat. Within 5 hours of exposure to 
heat conditions, the 51mM worms in the 35 oC, 37 oC, and 40 oC have a significant (p<0.0001) 
increase in protein aggregates compared to their baseline, 0h. 37 oC heat administration for 5 
hours causes aggregation and worm death. Of the 20 worms screened for 37 oC, 13 of the 
worms died from heat stress. 40 oC may also cause deaths, but the sample (n=5) size was much 
lower than that of the 37 oC. In addition, within 5 hours of exposure to heat conditions, the 
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51mM worms in the 35 oC, 37 oC, and 40 oC have a significant difference (p<0.0001) to their 
baseline, 0h. Additionally, 35 oC, 37 oC, and 40 oC are still significantly (p<.0104) different 
compared to the control of 20 oC at the same time point. 
 
Figure 5G. Glutamine aggregation increases in relation to heat. Within 6 hours of exposure to 
heat conditions, the 51mM worms in the 35 oC, 37 oC, and 40 oC have a significant difference 
(p<0.0001) to their baseline, 0h. Glutamine aggregation increases in relation to heat.  
6 hours of heat stress without recovery, is an adequate time to observe a significant (p<7.3x10-
6) development of puncta at 37o C, and 40o C compared to 20o C  baseline. In the experiments 
that made up this data set, there were 10 worms screen in 37o C conditions and none were 
dead. However, 2 were missing and may have climbed out due to the stressful conditions.  
 
Figure 5H. Hypertonic stress and heat stress significantly increase glutamine aggregation 
compared to just heat stress. Within 6 hours of exposure to heat conditions and 1 hour of 
recovery, the 200mM worms in the 37 oC and 40 oC have a significant difference (p<0.0002) to 
their baseline, 0h. At 6 hours of exposure to heat conditions and 1 hour of recovery, the 
200mM worms in the 35o C, 37o C, have a significant difference (p<0.0002) to their baseline at 
Hour 0. Additionally, 37o C, and 40 oC are still significantly (p<.0005) different compared to the 
control of 20 oC at the same time point. None of the worms died over the administration. It is 
possible that the “dead worms” from the 51mM up to 6 hours of heat administration were still 
alive, but just shocked from the heat and did not move when prodded with the worm pick with 
no response.  
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DISCUSSION 
 
7 experiments were pooled together. The data demonstrates that there is a significant increase 
in the number of protein aggregates with the increase in temperature in isotonic conditions. 
The number of protein aggregates in osmotic and heat stress is triple the amount of just heat 
stress. This matches the results of previous experiments that showed an increase in the number 
of protein aggregates in the hyperosmotic group. Hypertonic stress and heat stress significantly 
increase glutamine aggregation (p<2.01x10-7, p<0.008) compared to just heat stress at 37 oC, and 
40 oC.  
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CHAPTER 6 – STATIN EFFECTS ON COMBINED HEAT AND HYPERTONIC STRESS-INDUCED 
PROTEIN DAMAGE  
 
  
Figure 6. Effect of pure atorvastatin salt and heat stress(40oC) on glutamine aggregate 
formation in isotonic conditions. A: Hour 0, aggregate count. B: Hour 7, aggregate count. 
Number of worms tested (n=90 total): n=45 (0 MeOH), n=41 (1mM) (Table 7). * represents 
statistically significant (p<0.05) differences between atorvastatin salt dose and respective 0 
MeOH control. a represents statistically significant (p<0.05) differences between experimental 
conditions and respective baseline (0h). Number of worms tested (n=48 total): n=12 (0 MeOH), 
n=12 (0.25mM), n=12 (0.375mM), n=12 (0.5mM) (Table 10). 
 
RESULTS 
Figure 6A. Glutamine variability is not present at baseline, 0h. There is no significant difference 
between any condition and control, 0 MeOH.  
 
Figure 6B. Following 1 hour of heat exposure at 40oC and 6 hours of recovery, there is 
significant (p<2.56 x 10-8) difference between every condition and their baseline. In addition, 
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0.375mM and 0.5mM statin doses have significantly (p<0.04) more puncta at hour 7 compared 
to the 0mM statin dose in concomitant stress of 40oC. 
 
DISCUSSION 
As demonstrated in previous experiments, paired hyperosmotic (200mM) and Statin stress 
increase more protein aggregation over time than only statin stress. Similarly, statin paired with 
heat stress (40oC) increases (p<0.04) more protein aggregation over time than only heat stress. 
Statin stress in conjugation with heat stress, increase protein aggregation. In isotonic conditions 
(51mM NaCl), higher statin administration (0.5mM) significantly (p<0.0004) increases protein 
aggregation compared to no statin administration. With atorvastatin salt stress and 
concomitant heat stress, worms exhibit an greater amount of protein damage than just 
concomitant heat stress. Statins exacerbate protein aggregation during heat stress. This 
matches our previous data that shows individual heat and individual statin stress experiments 
increase protein aggregation.  
 
 
Figure 7. Effect of pure atorvastatin salt and heat stress (37oC)on glutamine aggregate 
formation in hypertonic conditions. A: 0h, aggregate count. B: 5h, aggregate count. * 
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represents statistically significant (p<0.05) differences between atorvastatin salt dose and 
respective 0 MeOH control. a represents statistically significant (p<0.05) differences between 
experimental conditions and respective baseline (0h). b represents statistically significant 
(p<0.05) differences between isotonic/dehydrated (51mM) vs. hypertonic/dehydrated 
(200mM) conditions. Number of worms tested (n=90 total): n=45 (0 MeOH), n=45 (1mM) (Table 
11). 
 
RESULTS 
Figure 7A. Glutamine aggregation varies at baseline, requiring 0 time point controls within 
experiments, per worm. Glutamine aggregates were counted to determine whether there is 
significant variability among worms in different experimental conditions at the start of the 
experiment (within 5 minutes of treatment). There is variability in number of puncta among 
healthy worms placed onto experimental conditions, thus it is important to determine the 
baseline variability in interpreting any effects observed with drug and/or stress treatments on 
glutamine aggregation. The hypertonic 1mM atorvastatin group is significantly (p<0.02) smaller 
than the isotonic group 1mM atorvastatin group within 5 minutes of putting the worms onto 
plates.  
 
Figure 7B. Hypertonic stress and heat stress significantly increase glutamine aggregation 
compared. Following 5 hours of heat exposure at 37o C, there is a significant (p<4.49x10-11) 
increase in all groups with respect to their baseline, 0h. In addition, there is also a significant 
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(p<0.006) increase from the isotonic to the hypertonic groups for both 0 MeOH and 1 MeOH 
groups.   
 
DISCUSSION 
Statin administration in conjugation with both heat stress and hypertonic stress, leads to the 
greatest amount of protein aggregation. With concomitant hypertonic (200mM NaCl) and heat 
stress, statin administration leads to the greatest amount of protein aggregation. The 
dehydrated (200mM NaCl) condition has significantly (p<0.006) more protein aggregates than 
the hydrated (51mM NaCl) condition with the same statin and heat stresses. This matches our 
data that even without statin administration, there is also significantly more protein aggregates 
(p<2.03x10-6) in the dehydrated state compared to the hydrated state under heat stress. When 
statin administration is further paired with hypertonic stress under hot conditions, there is the 
greatest amount of protein damage.  
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CHAPTER 7 –SUMMARY AND CONCLUSIONS 
 
Our results show that heat and dehydration stress, exacerbates muscular damage in C. elegans 
administered statins. Protein aggregation is dose related to both heat, hypertonic environment, 
and statins. In summary, statins cause proteins to unfold and aggregate leading to an increased 
number of puncta that quantify muscular damage. Heat and hypertonic environments also lead 
to an increased number of puncta. When statins are combined with heat and hypertonic 
environments, there is the greatest amount of muscular damage.  
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Appendix 
 
Table 4. Survival of worms of osmotic and atorvastatin pill stress for Hour 0 – Hour 4.  
Hour 0 51 200 51 200 51 200 51 200
0 additive 18 18 0 0 0 0 18 18
0 MeOH 54 54 0 0 0 0 54 54
0.1 18 18 0 0 0 0 18 18
0.125 18 18 0 0 0 0 18 18
0.25 18 18 0 0 0 0 18 18
0.375 18 18 0 0 0 0 18 18
0.5 18 18 0 0 0 0 18 18
0.75 18 18 0 0 0 0 18 18
1 36 36 0 0 0 0 36 36
Hour 2 51 200 51 200 51 200 51 200
0 additive 9 18 0 0 0 0 9 18
0 MeOH 54 54 0 0 0 3 54 51
0.1 18 18 0 0 0 0 18 18
0.125 18 18 0 0 2 1 16 17
0.25 18 18 0 0 2 0 16 18
0.375 18 18 0 0 0 0 18 18
0.5 18 18 0 8 6 0 12 10
0.75 18 18 7 7 0 0 11 11
1 36 36 14 23 5 2 17 11
Hour 4 51 200 51 200 51 200 51 200
0 additive 9 9 0 0 0 0 9 9
0 MeOH 45 45 0 0 2 4 43 41
0.1 18 18 0 0 0 0 18 18
0.125 9 9 0 0 1 0 8 9
0.25 18 18 0 5 2 0 16 13
0.375 18 18 0 0 0 0 18 18
0.5 18 18 1 16 6 0 11 2
0.75 18 18 10 13 0 0 8 5
1 27 27 17 26 3 0 7 1
Total Worms Dead Can't Find Total Alive Screened
Total Alive ScreenedCan't FindDeadTotal Worms
Total Worms Dead Can't Find Total Alive Screened
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Table 5. Survival of worms in osmotic and atorvastatin pill stress conditions for Hour 6 – Hour 8 
Hour 6 51 200 51 200 51 200 51 200
0 additive 9 18 0 0 0 0 9 18
0 MeOH 45 54 0 0 2 4 43 50
0.1 18 18 0 0 0 0 18 18
0.125 9 18 1 0 0 0 8 18
0.25 18 18 0 10 4 0 14 8
0.375 18 18 0 3 0 1 18 14
0.5 18 18 4 16 6 0 8 2
0.75 18 18 12 14 0 0 6 4
1 27 36 19 29 3 0 5 7
36 72
Hour 8 51 200 51 200 51 200 51 200
0 additive no data for 0 additive at hour 80 0 0 0
0 MeOH 36 36 0 0 1 4 35 32
0.1 18 18 0 0 0 0 18 18
0.125 no data for .125 additive at hour 80 0 0 0
0.25 18 18 0 11 4 0 14 7
0.375 18 18 0 3 0 1 18 14
0.5 18 18 4 17 5 0 9 1
0.75 18 18 12 15 0 0 6 3
1 18 18 13 18 2 0 3 0
Total Worms Dead Can't Find Total Alive Screened
Total Worms Dead Can't Find Total Alive Screened
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Table 6. Survival of worms in osmotic and atorvastatin salt stress conditions for Hour 0 – Hour 4 
Hour 0 51 200 51 200 51 200 51 200
0 H20 9 9
0 MeOH 45 9 45 9
0.25 27 27
0.375 27 27
0.5 27 27
1 MeOH 18 9 18 9
1 H20 9 9
Hour 2 51 200 51 200 51 200 51 200
0 H20 9 9
0 MeOH 45 9 45 9
0.25 27 27
0.375 27 27
0.5 27 27
1 MeOH 18 9 18 9
1 H20 9 9
Hour 4 51 200 51 200 51 200 51 200
0 H20 9 9
0 MeOH 45 9 45 9
0.25 27 27
0.375 27 27
0.5 27 4 23
1 MeOH 18 9 18 9
1 H20 9 9
Total Worms Dead Can't Find Total Alive Screened
Total Worms Dead Can't Find Total Alive Screened
Total Worms Dead Can't Find Total Alive Screened
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Table 7. Survival of worms in osmotic and atorvastatin salt stress conditions for Hour 6 – Hour 8 
Hour 6 51 200 51 200 51 200 51 200
0 H20 9 9
0 MeOH 45 9 45 9
0.25 27 27
0.375 27 27
0.5 27 3 1 23
1 MeOH 18 9 18 9
1 H20 9 9
Hour 8 51 200 51 200 51 200 51 200
0 H20 9 9
0 MeOH 45 9 45 9
0.25 27 27
0.375 27 27
0.5 27 5 1 21
1 MeOH 18 9 18 9
1 H20 9 9
Total Worms Dead Can't Find Total Alive Screened
Total Worms Dead Can't Find Total Alive Screened
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Table 8. Survival of worms in osmotic and heat stress conditions for Hour 0 – Hour 3 
Hour 0 51 200 51 200 51 200 51 200
20° C 30 5 30 5
35° C 25 25
37° C 30 5 30 5
40° C 5 5 5 5
Hour 1 51 200 51 200 51 200 51 200
20° C 15 15
35° C 15 15
37° C 15 15
40° C
Hour 2 51 200 51 200 51 200 51 200
20° C 15 15
35° C 15 15
37° C 15 15
40° C
Hour 3 51 200 51 200 51 200 51 200
20° C 10 10
35° C 10 10
37° C 10 10
40° C
Total Worms Dead Can't Find Total Alive Screened
Total Worms Dead Can't Find Total Alive Screened
Total Worms Dead Can't Find Total Alive Screened
Total Worms Dead Can't Find Total Alive Screened
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Table 9. Survival of worms in osmotic and heat stress conditions for Hour 4 – Hour 7 
Hour 4 51 200 51 200 51 200 51 200
20° C 15
35° C 10
37° C 15 10 5
40° C
Hour 5 51 200 51 200 51 200 51 200
20° C 20
35° C 15
37° C 20 13 7
40° C 5 1
Hour 6 51 200 51 200 51 200 51 200
20° C 10
35° C 10
37° C 10 2
40° C 5 1
Hour 7 51 200 51 200 51 200 51 200
20° C 5
35° C
37° C 5 5
40° C 5
Total Worms Dead Can't Find Total Alive Screened
Total Worms Dead Can't Find Total Alive Screened
Total Worms Dead Can't Find Total Alive Screened
Total Worms Dead Can't Find Total Alive Screened
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Table 10. Survival of worms in atorvastatin salt stress conditions for at 40oC. 
Hour 0 51 200 51 200 51 200 51 200
0 MeOH 12 12
0.25 12 12
0.375 12 12
0.5 12 12
Hour 7 51 200 51 200 51 200 51 200
0 MeOH 12 12
0.25 12 12
0.375 12 12
0.5 12 1 11
Total Worms Dead Can't Find Total Alive Screened
Total Worms Dead Can't Find Total Alive Screened
 
 
Table 11. Survival of worms in osmotic, and atorvastatin salt stress conditions for at 37oC. 
Hour 0 51 200 51 200 51 200 51 200
0 MeOH 27 18 27 18
1 27 18 27 18
Hour 5 51 200 51 200 51 200 51 200
0 MeOH 27 18 27 18
1 27 18 3 1 24 17
Total Worms Dead Can't Find Total Alive Screened
Total Worms Dead Can't Find Total Alive Screened
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